ATPS-55 INFLUENCE OF MAPK AND PI3K PATHWAY MUTATIONS ON RESPONSE TO TARGETED INHIBITORS

od McNeill, Robert S., Canoutas, Demitra A., Schmid, Ralf S., Bash, Ryan E., Constance, Brian H., Azam, Salma H., Reuther, Rachel A., Johnson, Gary L., Miller, C. Ryan
izdano v Neuro Oncol (2015)

PIK3CA missense mutations promote glioblastoma pathogenesis, but do not enhance targeted PI3K inhibition

od McNeill, Robert S., Stroobant, Emily E., Smithberger, Erin, Canoutas, Demitra A., Butler, Madison K., Shelton, Abigail K., Patel, Shrey D., Limas, Juanita C., Skinner, Kasey R., Bash, Ryan E., Schmid, Ralf S., Miller, C. Ryan
izdano v PLoS One (2018)

Combination therapy with potent PI3K and MAPK inhibitors overcomes adaptive kinome resistance to single agents in preclinical models of glioblastoma

od McNeill, Robert S, Canoutas, Demitra A, Stuhlmiller, Timothy J, Dhruv, Harshil D, Irvin, David M, Bash, Ryan E, Angus, Steven P, Herring, Laura E, Simon, Jeremy M, Skinner, Kasey R, Limas, Juanita C, Chen, Xin, Schmid, Ralf S, Siegel, Marni B, Van Swearingen, Amanda E D, Hadler, Michael J, Sulman, Erik P, Sarkaria, Jann N, Anders, Carey K, Graves, Lee M, Berens, Michael E, Johnson, Gary L, Miller, C Ryan
izdano v Neuro Oncol (2017)